Targeting ketone body metabolism to treat fatty liver disease.

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of Pharmacy and Pharmaceutical Sciences Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI:10.3389/jpps.2024.13375
Sora Kwon, Reshani Jeyaratnam, Kyoung-Han Kim
{"title":"Targeting ketone body metabolism to treat fatty liver disease.","authors":"Sora Kwon, Reshani Jeyaratnam, Kyoung-Han Kim","doi":"10.3389/jpps.2024.13375","DOIUrl":null,"url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disorder marked by excessive accumulation of lipids within the liver. If untreated, this condition can progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma (HCC). Given the liver's pivotal role in glucose and fatty acid metabolism, disruptions in these processes are commonly observed in MASLD. Ketone bodies, crucial energy metabolites primarily produced in the liver, are also closely related to the progression of MASLD. Recent studies have demonstrated that disrupted ketogenesis not only accompanies MASLD, but may also play a causal role in its development and progression. Moreover, activation of the ketogenic pathway has been suggested as a promising strategy for reducing excessive hepatic fat accumulation. This review focuses on the regulation of ketogenesis in MASLD, emphasizing the significance of dietary and pharmacological interventions as potential therapeutic approaches to treat fatty liver disease.</p>","PeriodicalId":50090,"journal":{"name":"Journal of Pharmacy and Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471530/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/jpps.2024.13375","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disorder marked by excessive accumulation of lipids within the liver. If untreated, this condition can progress to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma (HCC). Given the liver's pivotal role in glucose and fatty acid metabolism, disruptions in these processes are commonly observed in MASLD. Ketone bodies, crucial energy metabolites primarily produced in the liver, are also closely related to the progression of MASLD. Recent studies have demonstrated that disrupted ketogenesis not only accompanies MASLD, but may also play a causal role in its development and progression. Moreover, activation of the ketogenic pathway has been suggested as a promising strategy for reducing excessive hepatic fat accumulation. This review focuses on the regulation of ketogenesis in MASLD, emphasizing the significance of dietary and pharmacological interventions as potential therapeutic approaches to treat fatty liver disease.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
针对酮体代谢治疗脂肪肝。
代谢功能障碍相关性脂肪性肝病(MASLD)是一种以肝脏内脂质过度积聚为特征的代谢性疾病。如不及时治疗,这种疾病可发展为代谢功能障碍相关性脂肪性肝炎(MASH)、肝纤维化、肝硬化,最终发展为肝细胞癌(HCC)。鉴于肝脏在葡萄糖和脂肪酸代谢中的关键作用,这些过程的紊乱在 MASLD 中很常见。酮体是主要在肝脏中产生的重要能量代谢产物,也与 MASLD 的进展密切相关。最近的研究表明,酮体生成紊乱不仅伴随着 MASLD,还可能在其发生和发展过程中起着因果作用。此外,激活生酮途径被认为是减少肝脏脂肪过度积累的一种有前途的策略。这篇综述重点探讨了MASLD中的生酮调节,强调了饮食和药物干预作为治疗脂肪肝的潜在方法的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
29
审稿时长
6-12 weeks
期刊介绍: The Journal of Pharmacy and Pharmaceutical Sciences (JPPS) is the official journal of the Canadian Society for Pharmaceutical Sciences. JPPS is a broad-spectrum, peer-reviewed, international pharmaceutical journal circulated electronically via the World Wide Web. Subscription to JPPS is free of charge. Articles will appear individually as soon as they are accepted and are ready for circulation.
期刊最新文献
Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles. Expanding the eligibility criteria for drugs in Canada's time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines. Targeting ketone body metabolism to treat fatty liver disease. Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study. Evaluation of the rational prescription of linezolid, the prevalence of thrombocytopenia and major drug interactions in patients with cardiovascular diseases: are there any cautions?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1